Title: Microalbuminuria reduction with early pharmacotherapeutic intervention for blood pressure control in cases of hypertensive T2DM subjects.
Intern. Jour. of Diabetes. July 2019: 4-8 subjects of T2DM who were having microalbuminuria, [1] [2] [3] [4] in its reduction in comparison to a delayed initiation for the same. The outcome would help to co-relate the importance of achieving BP targets early in the course of disease progression of T2DM subjects as outlined in various trials. [5] [6] [7] [8] [9] [10] [11] It would also help to reflect the importance of alterations in the comorbidity for ESRD in the natural history of T2DM subjects. [12] [13] [14] [15] Sanjay Sud et al.
MATeRIAlS And MeThOdS
The inclusion criteria were:
• Nonpregnant adults (>18 years of age)
• T2DM (HbA1c ≥7.5% but <10 %)
• Hypertensive (BP >130/80 mm of Hg but <160/100 mm of Hg) • Drug naïve (for hypertension)
• Microalbuminuric (UACR of 30-300 mg/gm) • eGFR (CKD-EPI) ≥60 mL/min/1.73 m 2 Informed consent with validated documents as mandated was collected from the patients who fitted the above-mentioned criteria. The patients included, were divided in two groups, Table 1 and Table 2 .
On the first visit
Those in Group A were given standard up-titration of antihyperglycemic treatment to target the glycemic goal of HbA1c <7% and advised to follow DASH regimen and lifestyle modification for hypertension control, but no pharmacotherapy was initiated for hypertension. Group B were given the same advice but in addition prescribed the ARB -Azilsartan in 40 mg/day.
All patients were receiving/prescribed a statin in both the Groups A and B which was continued for the entire duration of the study (6 months). Microalbumin level (UACR), was recorded for each patient along with their BP and HbA1c. Patients in both the groups were followed up and advised to come back for the second visit after 3 months.
On the second visit
Those in Group A were continued on standard titration of antihyperglycemic treatment to target the glycemic goal of HbA1c <7% and added on Azilsartan in 40 mg/ day to control the BP to target goal of <130/80 mm of Hg.
Those in Group B were also advised titration of antihyperglycemic treatment as above and uptitration of the dosage for Azilsartan to 80 mg, if 40 mg/day of Azilsartan did not help to achieve the target BP goal of <130/80 mm of Hg.
UACR was recorded for each patient along with their BP and HbA1c, like the first visit.
Patients in both the groups were followed up and advised to come back for the third visit after 3 months.
On the third and final visit (6 months after the first visit).
UACR was recorded for each patient along with their BP and HbA1c, like the previous two visits.
